{"disease":{"id":"neoadjuvant-non-small-cell-lung-cancer","name":"neoadjuvant non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06734702","title":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":497,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06682884","title":"Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}